## **Engro Fertilizers Limited**

**Result Review & Key Takeaways** 

**PSX: EFERT** Bloomberg: EFERT.PA **Reuters: ENGR.KA** 

# EFERT: 4QCY21 Result Review & Analyst Briefing Takeaways

- EFERT posted CY21 net profit of PKR 21.1bn (EPS PKR 15.80) compared to net profit of PKR 18.3bn (EPS PKR 13.58) in CY20. 4QCY21 EPS of the company stood at PKR 4.62, down 9% YoY. Along with the result, the company also announced a cash dividend of PKR 5.0/share for 4Q taking the CY21 DPS to PKR 15.0 compared to DPS of PKR 13.0 during same period last year.
- The company's urea production was down by 7% YoY to 2.1mn tons during CY21 due to its Enven plant turnaround for 22 days during 3Q. During CY21, urea sales of the company increased by 12% YoY to 2.3mn tons due to higher urea inventory available at the beginning of year.
- Finance cost of the company during CY21 clocked in at PKR 1.6bn, down by ~50% YoY.
- Highest ever PAT of PKR 21.1bn for CY21 is supported by one-offs of around PKR 1.7bn. These include reassessment of depreciation rate, inventory gain (earlier procurement of DAP) and sales to registered dealers.
- Going forward, the management sees urea demand to hover around 6.1mn tons due to increase in area under cultivation (up by ~2mn hectares in last 2 years), use of hybrid seeds, and increase in urea applicability per hectare with change in farming methods.
- The company is paying concessionary rates for gas due to the stay order. Meanwhile, following prudent approach company is booking gas cost on non-concessionary rates.
- The management disclosed that the company is gearing up for further avenues. However, current dividend stream will continue till new plans are finalized.
- We recommend 'HOLD' on EFERT, as stock is offering capital downside of 5.3% and a dividend yield of 14.26%.

Financial Estimates (PKR mn)						
	4QCY20	4QCY21	YoY	CY20	CY21	YoY
Net Sales	27,708	39,621	43%	105,846	132,363	25%
Cost of Sales	18,321	26,571	45%	71,591	88,289	23%
Gross Profit	9,387	13,050	39%	34,255	44,074	29%
Dist. & Admin. Exp.	3,140	3,074	-2%	10,365	10,430	1%
Other Income	1,660	362	-78%	2,666	1,790	-33%
Other Charges	126	956	659%	1,905	2,641	39%
Finance cost	473	337	-29%	3,236	1,602	-50%
Other gains (losses)/GIDC	-	(787)	NM	-	(1,301)	NM
Profit Before Tax	7,309	8,258	13%	21,415	29,890	40%
Taxation	549	2,086	280%	3,165	8,798	178%
Net Income	6,760	6,172	-9%	18,250	21,093	16%
EPS	5.06	4.62	-9%	13.58	15.80	16%
DPS	4.00	5.00		13.00	16.50	

Source: Company Accounts, Akseer Research

	CY18A	CY19A	CY20A	CY21A	CY22F	CY23F
EPS	13.04	12.63	13.58	15.80	13.36	12.44
EPS Growth	56%	-3%	7%	16%	-15%	-7%
DPS	11.00	13.00	13.00	15.00	12.00	11.00
PER	6.5	6.7	6.2	5.3	6.3	6.8
Dividend Yield	13.1%	15.4%	15.4%	17.8%	14.3%	13.1%
EV/EBITDA	4.6	4.0	4.5	3.3	3.8	3.9
P/B	2.5	2.6	2.4	2.4	2.3	2.2
ROE	38.3%	39.0%	38.8%	44.1%	36.0%	32.2%

Source: Company Accounts, Akseer Research





## **Pakistan Research**

Key Data	
PSX Ticker	EFERT
Target Price (PKR)	80.0
Current Price (PKR)	84.1
Upside/(Downside) (%)	-5.3%
Dividend Yield (%)	14.26%
Total Return (%)	9.0%
12-month High (PKR)	86.0
12-month Low (PKR)	61.81
Outstanding Shares (mn)	1,335
Market Cap (PKR mn)	112,365
Year End	December

Source: Company Accounts, Akseer Research

#### **Muhammad Atif** muhammad.atif@akseerresearch.com



#### **Valuation Basis**

Our PT for Engro Fertilizers Limited (EFERT) has been computed using Free cash flow to equity (FCFE) method. We have used a risk-free rate of 12.0%, beta of 1.0 & market risk premium of 6% to arrive at cost of equity of 18.0%.

#### **Investment Thesis**

We have a 'HOLD' recommendation on the stock based on our PT of 80/share. Following the recent price appriciation, the stock is offering capital downside of 5.3% and dividend yield of 14.3%.

#### Risks

Key downside risks to our investments thesis are: 1) gas supply curtailment, 2) lower than anticipated fertilizer demand, and 3) lower than expected fertilizer prices.

## **Company Description**

Engro Fertilizers Limited is engaged in manufacturing, purchasing and marketing of fertilizers. Engro Fertilizers Limited is a wholly owned subsidiary of Engro Corporation Limited.

## **Financial Highlights - EFERT**

Income Statement (PK	R mn)					
	CY18A	CY19A	CY20A	CY21A	CY22F	CY23F
Net sales	109,197	121,355	105,846	132,363	125,458	129,814
Cost of sales	73,880	81,815	71,591	88,289	86,632	92,100
Gross Profit	35,316	39,540	34,255	44,074	38,826	37,713
SG & A	9,593	9,985	10,365	10,430	10,853	11,571
<b>Operating Profit</b>	25,723	29,555	23,890	33,644	27,973	26,142
Other income	2,062	4,352	2,549	1,790	1,400	883
Other charges	1,432	2,623	1,905	2,641	2,223	2,070
Finance cost	2,071	3,887	3,236	1,602	1,549	1,303
Profit before tax	24,282	27,398	21,298	29,890	25,119	23,391
Taxation	6,869	10,526	3,165	8,798	7,284	6,783
Profit after tax	17,414	16,871	18,133	21,093	17,834	16,607

Source: Company Accounts, Akseer Research

Balance sheet (PKR mn)						
	CY18A	CY19A	CY20A	CY21E	CY22F	CY23F
PPE	68,204	65,924	65,646	63,020	61,129	59,295
Other LT assets	4,630	5,235	5,247	5,129	5,030	4,947
Non-Current Assets	72,834	71,159	70,892	68,149	66,160	64,242
Current assets	44,887	55,888	60,821	50,792	40,968	39,547
Total Assets	117,721	127,047	131,713	118,941	107,127	103,789
Non-Current liabilities	33,069	34,632	35,975	24,450	16,295	10,937
Current liabilities	39,129	49,135	49,007	46,698	41,228	41,329
Total Liabilities	72,198	83,767	84,983	71,148	57,523	52,265
Equity	45,523	43,279	46,731	47,794	49,605	51,524
Total Equity & liabilities	117,721	127,047	131,713	118,941	107,127	103,789

Source: Company Accounts, Akseer Research

Cashflow statement (PKR mn)						
	CY18A	CY19A	CY20A	CY21E	CY22F	CY23F
Net Income	17,414	16,871	18,133	21,093	17,834	16,607
Non-cash Charges	5,195	5,677	5,343	5,414	5,179	5,007
<b>Operating Cash flows</b>	21,650	21,786	32,954	17,490	24,625	21,375
FCFF	18,660	20,782	30,645	15,833	22,436	19,127
Net borrowings	-4,330	1,182	8,242	-13,456	-9,206	-5,335
FCFE	12,845	19,571	36,131	1,246	12,130	12,867
Net change in cash	-1,066	2,684	198	-4,064	321	1,310
Closing cash	730	3,413	3,611	-452	-131	1,178

Source: Company Accounts, Akseer Research

#### Disclaimer

This report has been prepared and marketed jointly by Akseer Research (Pvt) Limited and Alpha Capital (Pvt) Limited, hereinafter referred jointly as "JV" and is provided for information purposes only. Under no circumstances this is to be used or considered as an offer to sell or solicitation of any offer to buy. While reasonable care has been taken to ensure that the information contained therein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeness and it should not be relied upon as such. From time to time, the JV and/or any of their officers or directors may, as permitted by applicable laws, have a position, or otherwise be interested in any transaction, in any securities directly or indirectly subject of this report. This report is provided only for the information of professionals who are expected to make their own investment decisions without undue reliance on this report. Investments in capital markets are subject to market risk and the JV accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. In particular, the report takes no account of the investment objectives, financial situation and particular needs of investors, who should seek further professional advice or rely upon their own judgment and acumen before making any investment. The views expressed in this report are those of the JV's Research Department and do not necessarily reflect those of the JV or its directors. Akseer Research and Alpha Capital as firms may have business relationships, including investment--banking relationships, with the companies referred to in this report. The JV or any of their officers, directors, principals, employees, associates, close relatives may act as a market maker in the securities of the companies mentioned in this report, may have a financial interest in the securities of these companies to an amount exceeding 1% of the value of the securities of these companies, may serve or may have served in the past as a director or officer of these companies, may have received compensation from these companies for corporate advisory services, brokerage services or underwriting services or may expect to receive or intend to seek compensation from these companies for the aforesaid services, may have managed or co-managed a public offering, take-over, buyback, delisting offer of securities or various other functions for the companies mentioned in this report.

All rights reserved by the JV. This report or any portion hereof may not be reproduced, distributed or published by any person for any purpose whatsoever. Nor can it be sent to a third party without prior consent of the JV. Action could be taken for unauthorized reproduction, distribution or publication.

#### Valuation Methodology

To arrive at our 12-months Price Target, the JV uses different valuation methods which include: 1). DCF methodology, 2). Relative valuation methodology, and 3). Asset-based valuation methodology.

#### **Ratings Criteria**

JV employs a three-tier ratings system to rate a stock, as mentioned below, which is based upon the level of expected return for a specific stock. The rating is based on the following with time horizon of 12-months.

Rating	Expected Total Return
Buy	Greater than or equal to +15%
Hold	Between -5% and +15%
Sell	Less than or equal to -5%

Ratings are updated to account for any development impacting the economy/sector/company, changes in analysts' assumptions or a combination of these factors.

## **Research Dissemination Policy**

The JV endeavours to make all reasonable efforts to disseminate research to all eligible clients in a timely manner through either physical or electronic distribution such as email, fax mail etc.

#### Analyst Certification

The research analyst, denoted by 'AC' on the cover of this report, has also been involved in the preparation of this report, and is a member of JV's Equity Research Team. The analyst certifies that (1) the views expressed in this report accurately reflect his/her personal views and (2) no part of his/her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.

#### **Contact Details**

## Akseer Research (Pvt) Limited

## Alpha Capital (Pvt) Limited

1st Floor, Shaheen Chambers, KCHS block 7 & 8, off. Shahrah-e-Faisal 3rd Floor, Shaheen Chambers, A-4 Central Commercial Area, Т: +92-21-34320359 -60

- E: info@akseerresearch.com

- KCH Society, Block 7 & 8, Near Virtual University, Karachi
- T: +92-21-38694242
- info@alfaadhi.net E: